References
- Carey L, Winer E and Viale Get al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683–92
- Gluz O, Liedtke C and Gottschalk Net al. Triple-negative breast cancer – current status and future directions. Ann Oncol 2009; 20:1913–27
- Miller K, Wang M and Gralow Jet al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76
- Yamamoto Y and Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341–51
- Liedtke C, Mazouni C and Hess KRet al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275–81
- Liedtke C, Yan K and Wu Yet al. Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. San Antonio Breast Cancer Symposium (SABCS). Cancer Res 2009;69: Abstract nr 2119
- Hess KR, Anderson K and Symmans WFet al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236–44
- Neve RM, Chin K and Fridlyand Jet al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515–27
- Irizarry RA, Hobbs B and Collin Fet al. Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249–64
- Gentleman RC, Carey VJ and Bates DMet al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80
- Lauss M, Kriegner A, Vierlinger K and Noehammer C. Characterization of the drugged human genome. Pharmacogenomics 2007;8:1063–73
- Ku JH, Shin JK and Cho MCet al. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol 2009;43:445–53
- Flamant L, Notte A and Ninane Net al. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 2010;9:191
- Lazier CB, Thomas LN and Douglas RCet al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58:130–44
- Das K, Lorena PD and Ng LKet al. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 2010;17:757–70
- Schmidt LJ, Murillo H and Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl 2004;25:944–53
- Zhong H, De Marzo AM and Laughner Eet al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830–5
- Mimeault M and Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013;17:30–54